Abzu discovered key biomarkers for successful clinical trial of siRNA therapeutic.

Simple models accurately predicted and explained key biomarkers for successful clinical trial test of siRNA designed to downregulate.

Checkmate Pharmaceuticals is a clinical stage biotechnology company focusing on harnessing the power of the immune system to combat cancer. Identifying these key biomarkers was pivotal in their sale to Regeneron.

Abzu revealed key biomarkers behind treatment response.

Your partner for precise and exceptional results.

We supported a single Computational Biologist (with expertise in target discovery and target validation in oncology) with full bioinformatics capabilities to identify the key biomarkers for clinical trial.

Abzu bioinformatician

A testament to innovation and collaboration.


Working with Abzu to analyze our clinical data has provided us with new insights and helped us generate new hypotheses for exploring the potential for a biomarker-based enrichment strategy across cancer.

Art Krieg, Chief Scientific Officer

Genetic biomarkers as indicators of treatment response.

We explored gene-signature interactions to identify and explain treatment responses.

Biomarker levels can reveal the biological processes that influence treatment efficacy — but only if there is an understanding of the “why” behind these processes.

Understanding which factors drive outcomes — and how they’re related — is a clear advantage for clinical trial success.


Less data, more discovery.

Make the most out of every piece of information.

Contrary to the data-heavy demands of black-box AI, our technology thrives on minimal data. This efficiency not only accelerates the discovery process, but also reduces your barrier to entry to develop new, innovative drugs.

Share this case study.

What can you an Abzu do together?

A partnership protects your targets and designs, ensuring a swift and unobstructed path to market.

Through an exclusive agreement, Abzu guarantees a commitment to confidentiality, focus, and unparalleled innovation. Maximize your investment and results with a partnership in disease understanding or drug design.

Accelerate your R&D with best-in-class in silico solutions.

Read more case studies from Abzu in disease understanding and drug design.

Abzu’s QLattice uniquely identified key “partner” genes involved in skin spaceflight response, a new discovery for how spaceflight damages skin.
Understanding how bears can hibernate without developing blood clots or muscle atrophy can help humans prepare for the future of space travel.
A strategic partnership with Contera Pharma included ASO and siRNA therapeutic designs and target identification.

Subscribe for
notifications from Abzu.

You can opt out at any time. We’re cookieless, and our privacy policy is actually easy to read.